Literature DB >> 23557333

The nuclear import receptor Kpnβ1 and its potential as an anticancer therapeutic target.

Pauline J van der Watt1, Catherine L Stowell, Virna D Leaner.   

Abstract

Many proteins require transport across the nuclear envelope, the physical barrier separating the nucleus from the cytoplasm. Karyopherin β (Kpnβ1) proteins are the major nuclear receptor proteins in the cell that cargo proteins across the nuclear envelope, allowing them to enter and exit the cell nucleus. Karyopherin β1, a major nuclear import receptor, plays an integral role in importing transcription factors, cell signaling proteins, cell cycle proteins, and so forth, into the nucleus, thus playing a crucial role in maintaining normal cell homeostasis. However, cancer cells appear to differentially regulate the expression of the Karyopherin β proteins, presumably in order to maintain increased nuclear transport rates, thus implicating this protein family as a target for cancer therapy. The role of Kpnβ1 in cancer is only now being elucidated, and recent work points to its potential usefulness as an anti-cancer target.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557333     DOI: 10.1615/critreveukargeneexpr.2013004845

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  14 in total

1.  Upregulation of KPNβ1 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis.

Authors:  Jia Zhu; Yingying Wang; Hua Huang; Qichang Yang; Jing Cai; Qiuhong Wang; Xiaoling Gu; Pan Xu; Shusen Zhang; Manhua Li; Haifang Ding; Lei Yang
Journal:  Tumour Biol       Date:  2015-08-05

2.  Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.

Authors:  Song He; Xiaobing Miao; Yaxun Wu; Xinghua Zhu; Xianjing Miao; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Xiaoyun Lu; Yali Chen; Yuchan Wang; Xiaohong Xu
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-23       Impact factor: 4.553

3.  The GTPase RAN regulates multiple steps of the centrosome life cycle.

Authors:  Patrizia Lavia
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

4.  Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma.

Authors:  Linlin Yang; Baoying Hu; Yixin Zhang; Songlin Qiang; Jin Cai; Wei Huang; Chen Gong; Tingting Zhang; ShuSen Zhang; Pan Xu; Xuming Wu; Jibin Liu
Journal:  Med Oncol       Date:  2015-03-21       Impact factor: 3.064

5.  Up-Regulation of KPNB1 Involves in Neuronal Apoptosis Following Intracerebral Hemorrhage in Adult Rats.

Authors:  Aihua Dai; Xiaorong Liu; Yu Zhang; Lijian Han; Liang Zhu; Haidan Ni; Rongrong Chen; Maohong Cao
Journal:  Neurochem Res       Date:  2015-08-25       Impact factor: 3.996

6.  KPNβ1 promotes palmitate-induced insulin resistance via NF-κB signaling in hepatocytes.

Authors:  Suxin Wang; Yun Zhao; Nana Xia; Wanlu Zhang; Zhuqi Tang; Cuifang Wang; Xiaohui Zhu; Shiwei Cui
Journal:  J Physiol Biochem       Date:  2015-10-09       Impact factor: 4.158

Review 7.  Off to the organelles - killing cancer cells with targeted gold nanoparticles.

Authors:  Mohamed Kodiha; Yi Meng Wang; Eliza Hutter; Dusica Maysinger; Ursula Stochaj
Journal:  Theranostics       Date:  2015-01-21       Impact factor: 11.556

8.  KPNB1 mediates PER/CRY nuclear translocation and circadian clock function.

Authors:  Yool Lee; A Reum Jang; Lauren J Francey; Amita Sehgal; John B Hogenesch
Journal:  Elife       Date:  2015-08-29       Impact factor: 8.140

9.  Importin-β/karyopherin-β1 modulates mitotic microtubule function and taxane sensitivity in cancer cells via its nucleoporin-binding region.

Authors:  Annalisa Verrico; Paola Rovella; Laura Di Francesco; Michela Damizia; David Sasah Staid; Loredana Le Pera; M Eugenia Schininà; Patrizia Lavia
Journal:  Oncogene       Date:  2019-09-06       Impact factor: 9.867

10.  Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.

Authors:  Chie Ishikawa; Masachika Senba; Naoki Mori
Journal:  Invest New Drugs       Date:  2020-09-21       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.